JP2010500291A5 - - Google Patents

Download PDF

Info

Publication number
JP2010500291A5
JP2010500291A5 JP2009523112A JP2009523112A JP2010500291A5 JP 2010500291 A5 JP2010500291 A5 JP 2010500291A5 JP 2009523112 A JP2009523112 A JP 2009523112A JP 2009523112 A JP2009523112 A JP 2009523112A JP 2010500291 A5 JP2010500291 A5 JP 2010500291A5
Authority
JP
Japan
Prior art keywords
antibody
csfr
csf
pharmaceutical composition
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009523112A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010500291A (ja
JP5235881B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2007/001127 external-priority patent/WO2008017126A1/en
Publication of JP2010500291A publication Critical patent/JP2010500291A/ja
Publication of JP2010500291A5 publication Critical patent/JP2010500291A5/ja
Application granted granted Critical
Publication of JP5235881B2 publication Critical patent/JP5235881B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009523112A 2006-08-11 2007-08-10 肺疾患病態の処理 Expired - Fee Related JP5235881B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2006904378 2006-08-11
AU2006904378A AU2006904378A0 (en) 2006-08-11 Treatment and prophylaxis of pulmonary disease conditions
PCT/AU2007/001127 WO2008017126A1 (en) 2006-08-11 2007-08-10 Treatment of pulmonary disease conditions

Publications (3)

Publication Number Publication Date
JP2010500291A JP2010500291A (ja) 2010-01-07
JP2010500291A5 true JP2010500291A5 (enExample) 2010-09-24
JP5235881B2 JP5235881B2 (ja) 2013-07-10

Family

ID=39032559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009523112A Expired - Fee Related JP5235881B2 (ja) 2006-08-11 2007-08-10 肺疾患病態の処理

Country Status (10)

Country Link
US (2) US8574572B2 (enExample)
EP (2) EP2056858B1 (enExample)
JP (1) JP5235881B2 (enExample)
AU (1) AU2007283463B2 (enExample)
CA (1) CA2661446C (enExample)
DK (1) DK2056858T3 (enExample)
ES (1) ES2506065T3 (enExample)
NZ (1) NZ574285A (enExample)
PL (1) PL2056858T3 (enExample)
WO (1) WO2008017126A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011014750A1 (en) * 2009-07-31 2011-02-03 Genentech, Inc. Inhibition of tumor metastasis using bv8- or g-csf-antagonists
CA2773552C (en) * 2009-09-15 2017-11-21 Csl Limited Treatment of neurological conditions
CA2795145C (en) * 2010-04-02 2019-01-22 Curna, Inc. Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
BR112013031943B1 (pt) * 2011-06-13 2021-10-13 Csl Limited Composição que compreende proteínas e anticorpos contra g-csfr
WO2016185385A1 (en) * 2015-05-18 2016-11-24 The University Of British Columbia Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of copd
JP6944701B2 (ja) * 2016-10-21 2021-10-06 国立大学法人山口大学 CD11bアンタゴニストを含む劇症型急性肺炎治療用組成物
ES2939461T3 (es) 2017-11-29 2023-04-24 Csl Ltd Método para tratar o prevenir la lesión por isquemia-reperfusión
WO2019178645A1 (en) 2018-03-23 2019-09-26 Csl Limited Method of treating asthma
US20220220209A1 (en) * 2018-12-04 2022-07-14 CSL Innovation Pty Ltd Method of treating neutrophilic conditions
JP2023533658A (ja) * 2020-06-04 2023-08-04 シーエスエル イノベーション プロプライアタリー リミティド 急性呼吸窮迫症候群を治療又は予防する方法
WO2025007195A1 (en) 2023-07-05 2025-01-09 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
BR9206313A (pt) 1991-07-25 1995-04-11 Idec Pharma Corp Anticorpos recombinantes para terapia humana.
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
WO1999055369A1 (en) 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
NZ538421A (en) 2002-08-23 2008-08-29 Inst Medical W & E Hall A method of treatment and prophylaxis
WO2006077501A2 (en) 2005-01-13 2006-07-27 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Decladinosyl-macrolides with anti-inflammatory activity
WO2006077504A2 (en) 2005-01-18 2006-07-27 Koninklijke Philips Electronics N.V. An algorithm for growing 4-connected cores in image segmentation
WO2007084485A2 (en) * 2006-01-13 2007-07-26 Battelle Memorial Institute Markers for assessing copd-related diseases

Similar Documents

Publication Publication Date Title
JP2010500291A5 (enExample)
Ng et al. Interleukin-11 signaling underlies fibrosis, parenchymal dysfunction, and chronic inflammation of the airway
JP2005530490A5 (enExample)
JP2011500003A5 (enExample)
JP2015519891A5 (enExample)
JP2016116520A5 (enExample)
JP2013504603A5 (enExample)
JP2007505627A5 (enExample)
JP2012505660A5 (enExample)
JP2008546390A5 (enExample)
JP2010528601A5 (enExample)
JP2012505657A5 (enExample)
JP2020500929A5 (enExample)
JP2011516410A5 (enExample)
JP2018510621A5 (enExample)
JP2013537423A5 (enExample)
JP2015511625A5 (enExample)
JP2008525033A5 (enExample)
Kay et al. Eosinophils and interleukin-5: the debate continues
KR20160119259A (ko) 낭포성 섬유증 및 cftr 이온 채널의 기능 결함과 관련된 기타 병태의 치료제로서 알기네이트 올리고머의 용도
JP2011526482A5 (enExample)
JP2014504857A5 (enExample)
CA2558212A1 (en) Interferon-beta for anti-virus therapy for respiratory diseases
JP2010540649A5 (enExample)
CN112996913A (zh) 寡聚核酸分子及其应用